Brokerages Set bluebird bio, Inc. (NASDAQ:BLUE) Price Target at $5.87

bluebird bio, Inc. (NASDAQ:BLUE) has received a consensus recommendation of “Hold” from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $5.87.

BLUE has been the topic of a number of recent analyst reports. Wedbush reduced their target price on bluebird bio from $1.72 to $1.68 and set a “neutral” rating on the stock in a report on Tuesday, March 19th. Royal Bank of Canada restated a “sector perform” rating and set a $6.00 price objective on shares of bluebird bio in a report on Wednesday, March 27th. William Blair reiterated a “market perform” rating on shares of bluebird bio in a report on Tuesday, January 9th. StockNews.com raised shares of bluebird bio to a “sell” rating in a report on Thursday, March 28th. Finally, HSBC dropped their price objective on bluebird bio from $2.31 to $1.02 and set a “reduce” rating on the stock in a research note on Tuesday, March 5th.

Institutional Trading of bluebird bio

A number of hedge funds have recently modified their holdings of the stock. Citigroup Inc. grew its position in shares of bluebird bio by 5.8% in the third quarter. Citigroup Inc. now owns 557,969 shares of the biotechnology company’s stock valued at $1,696,000 after purchasing an additional 30,532 shares during the last quarter. Deutsche Bank AG raised its stake in bluebird bio by 80.8% in the 3rd quarter. Deutsche Bank AG now owns 692,881 shares of the biotechnology company’s stock worth $2,106,000 after purchasing an additional 309,690 shares in the last quarter. Bleichroeder LP bought a new stake in bluebird bio in the 3rd quarter valued at about $2,736,000. Aigen Investment Management LP acquired a new position in shares of bluebird bio during the 3rd quarter worth approximately $34,000. Finally, Vanguard Group Inc. increased its holdings in shares of bluebird bio by 0.8% during the third quarter. Vanguard Group Inc. now owns 5,617,460 shares of the biotechnology company’s stock worth $17,077,000 after purchasing an additional 46,216 shares during the period. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Stock Performance

Shares of BLUE stock opened at $0.95 on Tuesday. The firm’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $2.07. The stock has a market cap of $104.20 million, a PE ratio of -1.31 and a beta of 0.74. bluebird bio has a 52-week low of $0.88 and a 52-week high of $5.53.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.